Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by equities researchers at Guggenheim in a report released on Thursday. They currently have a $200.00 price target on the specialty pharmaceutical company’s stock. Guggenheim’s price objective would suggest a potential upside of 52.77% from the company’s previous close. Other equities analysts have also issued […]
